CL2007003514A1 - Compuestos derivados de quinolina; procedimiento de preparacion de dichos compuestos; combinacion farmaceutica; y uso de los compuestos para preparar un medicamento para tratar una infeccion bacteriana. - Google Patents
Compuestos derivados de quinolina; procedimiento de preparacion de dichos compuestos; combinacion farmaceutica; y uso de los compuestos para preparar un medicamento para tratar una infeccion bacteriana.Info
- Publication number
- CL2007003514A1 CL2007003514A1 CL200703514A CL2007003514A CL2007003514A1 CL 2007003514 A1 CL2007003514 A1 CL 2007003514A1 CL 200703514 A CL200703514 A CL 200703514A CL 2007003514 A CL2007003514 A CL 2007003514A CL 2007003514 A1 CL2007003514 A1 CL 2007003514A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- quinolina
- prepare
- procedure
- preparation
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 3
- 208000035143 Bacterial infection Diseases 0.000 title 1
- 208000022362 bacterial infectious disease Diseases 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06125499 | 2006-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2007003514A1 true CL2007003514A1 (es) | 2008-07-11 |
Family
ID=38126091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL200703514A CL2007003514A1 (es) | 2006-12-06 | 2007-12-05 | Compuestos derivados de quinolina; procedimiento de preparacion de dichos compuestos; combinacion farmaceutica; y uso de los compuestos para preparar un medicamento para tratar una infeccion bacteriana. |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US8415475B2 (es) |
| EP (1) | EP2099758B1 (es) |
| JP (1) | JP5466011B2 (es) |
| KR (1) | KR101490222B1 (es) |
| CN (2) | CN104744361B (es) |
| AP (1) | AP2479A (es) |
| AR (1) | AR064151A1 (es) |
| AU (1) | AU2007328887B2 (es) |
| BR (1) | BRPI0720220B8 (es) |
| CA (1) | CA2669819C (es) |
| CL (1) | CL2007003514A1 (es) |
| CY (1) | CY1117766T1 (es) |
| DK (1) | DK2099758T3 (es) |
| EA (1) | EA016733B1 (es) |
| ES (1) | ES2573689T3 (es) |
| HK (1) | HK1208437A1 (es) |
| HR (1) | HRP20160585T1 (es) |
| HU (1) | HUE028769T2 (es) |
| IL (1) | IL199083A (es) |
| JO (1) | JO3271B1 (es) |
| ME (1) | ME02498B (es) |
| MX (1) | MX2009005978A (es) |
| MY (1) | MY181645A (es) |
| NO (1) | NO341983B1 (es) |
| NZ (1) | NZ576823A (es) |
| PL (1) | PL2099758T3 (es) |
| PT (1) | PT2099758E (es) |
| RS (1) | RS54794B1 (es) |
| SI (1) | SI2099758T1 (es) |
| TW (1) | TWI406659B (es) |
| UA (1) | UA100972C2 (es) |
| WO (1) | WO2008068267A1 (es) |
| ZA (1) | ZA200903950B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2576491T3 (es) | 2012-04-27 | 2016-07-07 | Janssen Pharmaceutica, N.V. | Derivados de quinolina antibacterianos |
| EA038350B1 (ru) | 2012-04-27 | 2021-08-12 | Янссен Фармацевтика Нв | Антибактериальные хинолиновые производные |
| ES2628365T3 (es) | 2012-10-16 | 2017-08-02 | Janssen Pharmaceutica N.V. | Moduladores de quinolinilo unidos a fenilo de ROR-GAMA-T |
| MX358508B (es) | 2012-10-16 | 2018-08-22 | Janssen Pharmaceutica Nv | Moduladores de quinolinilo unidos a metileno de receptor nuclear de acido retinoico-gamma-t. |
| US9303015B2 (en) | 2012-10-16 | 2016-04-05 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORγt |
| US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
| EP3057421B1 (en) | 2013-10-15 | 2019-11-20 | Janssen Pharmaceutica NV | Alkyl linked quinolinyl modulators of ror(gamma)t |
| CA2927182A1 (en) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | Quinolinyl modulators of ror.gamma.t |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| BR112017000764B1 (pt) * | 2014-07-14 | 2022-07-12 | Shanghai Jia Tan Pharmatech Co. Ltd. | Composto, método para preparar o composto e uso do composto |
| CN105330595B (zh) * | 2014-07-14 | 2019-12-10 | 上海嘉坦医药科技有限公司 | 吡啶衍生物及其作为抗分支杆菌的应用 |
| AU2016212116B2 (en) * | 2015-01-27 | 2021-07-15 | Janssen Pharmaceutica Nv | Dispersible compositions |
| WO2017121323A1 (zh) * | 2016-01-13 | 2017-07-20 | 辰欣药业股份有限公司 | 一种吡啶衍生物类化合物的制备方法及其中间体和晶型 |
| CN105601566A (zh) * | 2016-02-02 | 2016-05-25 | 张敏 | 一种护理烧伤后感染的药物组合物 |
| US10508097B2 (en) * | 2016-03-07 | 2019-12-17 | The Global Alliance For Tb Drug Development, Inc. | Antibacterial compounds and uses thereof |
| US11857352B2 (en) | 2016-09-06 | 2024-01-02 | The Research Foundation For The State University Of New York | Positron imaging tomography imaging agent composition and method for bacterial infection |
| CN111757879A (zh) * | 2018-01-29 | 2020-10-09 | 卡地拉健康护理有限公司 | 用作抗菌剂的杂环化合物 |
| CA3198350A1 (en) * | 2020-10-22 | 2022-04-28 | Lunella Biotech, Inc. | Mitochondrial atp inhibitors targeting the gamma subunit prevent metastasis |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2270123A1 (en) * | 1996-10-28 | 1998-05-07 | Department Of The Army, U.S. Government | Compounds, compositions and methods for treating antibiotic-resistant infections |
| PL222801B1 (pl) * | 2002-07-25 | 2016-09-30 | Janssen Pharmaceutica Nv | Pochodne chinoliny, ich zastosowanie, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca je |
| AP2188A (en) | 2004-01-23 | 2010-12-14 | Janssen Pharmaceutica Nv | Substituted quinolines and their use as mycobacterial inhibitors. |
| PT1711181E (pt) | 2004-01-23 | 2009-12-29 | Janssen Pharmaceutica Nv | Derivados quinolina e sua utilização como inibidores micobacterianos |
| AU2005210036B2 (en) | 2004-01-29 | 2010-12-23 | Janssen Pharmaceutica N.V. | Quinoline derivatives for use as mycobacterial inhibitors |
| EP1753427B1 (en) | 2004-05-28 | 2008-04-02 | Janssen Pharmaceutica N.V. | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases |
| DK1797115T3 (en) | 2004-09-28 | 2017-10-02 | Janssen Pharmaceutica Nv | BACTERIAL ATP SYNTHASE BINDING DOMAIN. |
| EE05394B1 (et) | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis |
| CA2528849C (en) * | 2005-06-08 | 2014-01-14 | Janssen Pharmaceutica N.V. | Quinoline derivatives as antibacterial agents |
| JO2855B1 (en) * | 2005-08-03 | 2015-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
| JO2952B1 (en) * | 2005-08-03 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
| JO2837B1 (en) * | 2005-08-03 | 2014-09-15 | جانسن فارمسيتكا ان في | Quinoline derivatives acting as antibacterial agents |
-
2007
- 2007-11-29 JO JOP/2007/0504A patent/JO3271B1/ar active
- 2007-12-04 RS RS20160374A patent/RS54794B1/sr unknown
- 2007-12-04 CA CA2669819A patent/CA2669819C/en active Active
- 2007-12-04 HU HUE07847811A patent/HUE028769T2/en unknown
- 2007-12-04 AU AU2007328887A patent/AU2007328887B2/en not_active Ceased
- 2007-12-04 MY MYPI20092283A patent/MY181645A/en unknown
- 2007-12-04 US US12/516,065 patent/US8415475B2/en active Active
- 2007-12-04 AP AP2009004874A patent/AP2479A/xx active
- 2007-12-04 CN CN201510088659.1A patent/CN104744361B/zh active Active
- 2007-12-04 JP JP2009539738A patent/JP5466011B2/ja active Active
- 2007-12-04 UA UAA200904716A patent/UA100972C2/ru unknown
- 2007-12-04 DK DK07847811.2T patent/DK2099758T3/en active
- 2007-12-04 MX MX2009005978A patent/MX2009005978A/es active IP Right Grant
- 2007-12-04 ME MEP-2016-109A patent/ME02498B/me unknown
- 2007-12-04 ES ES07847811.2T patent/ES2573689T3/es active Active
- 2007-12-04 PT PT07847811T patent/PT2099758E/pt unknown
- 2007-12-04 WO PCT/EP2007/063313 patent/WO2008068267A1/en active Application Filing
- 2007-12-04 SI SI200731779A patent/SI2099758T1/sl unknown
- 2007-12-04 EP EP07847811.2A patent/EP2099758B1/en active Active
- 2007-12-04 EA EA200970535A patent/EA016733B1/ru unknown
- 2007-12-04 CN CNA2007800449358A patent/CN101553470A/zh active Pending
- 2007-12-04 PL PL07847811T patent/PL2099758T3/pl unknown
- 2007-12-04 NZ NZ576823A patent/NZ576823A/en unknown
- 2007-12-04 BR BRPI0720220A patent/BRPI0720220B8/pt active IP Right Grant
- 2007-12-04 KR KR1020097012967A patent/KR101490222B1/ko active IP Right Grant
- 2007-12-05 AR ARP070105444A patent/AR064151A1/es unknown
- 2007-12-05 TW TW096146217A patent/TWI406659B/zh not_active IP Right Cessation
- 2007-12-05 CL CL200703514A patent/CL2007003514A1/es unknown
-
2009
- 2009-06-02 IL IL199083A patent/IL199083A/en active IP Right Grant
- 2009-06-05 ZA ZA200903950A patent/ZA200903950B/xx unknown
- 2009-07-06 NO NO20092542A patent/NO341983B1/no unknown
-
2015
- 2015-09-10 HK HK15108797.1A patent/HK1208437A1/xx unknown
-
2016
- 2016-05-31 HR HRP20160585TT patent/HRP20160585T1/hr unknown
- 2016-06-08 CY CY20161100496T patent/CY1117766T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2007003514A1 (es) | Compuestos derivados de quinolina; procedimiento de preparacion de dichos compuestos; combinacion farmaceutica; y uso de los compuestos para preparar un medicamento para tratar una infeccion bacteriana. | |
| CL2008001002A1 (es) | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. | |
| CL2008001003A1 (es) | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. | |
| CL2007003685A1 (es) | Compuestos derivados de indol con un anillo unido en las posiciones 4 y 5; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion viral. | |
| CL2007003684A1 (es) | Compuestos derivados de indol con un anillo unido en las posiciones 5 y 6; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion viral. | |
| CL2007001427A1 (es) | Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po | |
| CL2014000732A1 (es) | Compuestos derivados heterociclicos para su uso en la prevencion o tratamiento de una infeccion por flavivirus; metodo para su preparacion; y composicion farmaceutica que los comprende. | |
| CL2008001367A1 (es) | Compuestos derivados de heterociclos nitrogenados sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una infeccion bacteriana. | |
| CL2008000496A1 (es) | Compuestos derivados de purina; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades infecciosas, cancer, alergias y otras afecciones inflamatorias. | |
| CL2007002446A1 (es) | Compuestos derivados de morfolino pirimidina; composicion farmaceutica; y su uso para preparar un medicamento para producir un efecto antiproliferante. | |
| IL212435A (en) | Isoindulin compounds, their pharmaceutical compositions and their use in the preparation of drugs | |
| CL2012003632A1 (es) | Compuestos derivados de pirazolo[1,5-a]pirimidinas o una sal farmaceuticamente aceptable de los mismos; composicion farmaceutica que los comprende; y su uso para tratar una infeccion por virus pneumovirinae o una infeccion por virus sincicial respiratorio. | |
| CL2007003645A1 (es) | Compuestos parasiticidas derivados de aril-pirazoles sustituidos; compuestos intermediarios; composicion farmaceutica; y uso para tratar una infeccion parasitaria. | |
| BRPI0821115A2 (pt) | Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto | |
| CL2007000918A1 (es) | Compuestos derivados de enfumafungina, inhibidores de (1,3)-beta-d-glucanosintetasa; composicion farmaceutica; y uso para tratar una infeccion fungica. | |
| BRPI1013394A2 (pt) | "composto, composição farmacêutica, uso do composto, e, método para tratar um paciente infectado com virus da hepatite c." | |
| CL2007002284A1 (es) | Compuestos derivados de tetrazolilos macrociclicos; proceso de preparacion; composicion farmaceutica; y uso para tratar una infeccion viral de hepatitis c. | |
| UY31918A (es) | Compuestos de pirazol inhibidores de fgfr, composiciones farmaceuticas que los comprenden, procesos para su preparacion y su uso como medicamento | |
| UY30759A1 (es) | Compuestos quimicos | |
| BRPI0812738A2 (pt) | Composto, sal farmceuticamente aceitável, composição farmacêutica, uso de um composto, e, método par ao tratamento de uma infecção viral em um humano | |
| CL2012000319A1 (es) | Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística. | |
| BRPI0816255A2 (pt) | Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável | |
| BRPI1006040A2 (pt) | uso de composições farmacêuticas, tipo de curativo médico, e, tipo de caixa de medicamento | |
| WO2011012322A3 (en) | Synthesis and use of vildagliptin for the preparation of pharmaceutical dosage forms | |
| BRPI1009392A2 (pt) | "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica." |